In the July 9, 2014, Federal Register, FDA requested that any industry organizations interested in participating in the selection of a nonvoting industry representative to serve on the Center for Biologics Evaluation and Research's ("CBER") Cellular, Tissue, and Gene Therapies Advisory Committee notify FDA in writing. The chosen representative would represent industry interests on the committee. FDA also requested nominations for nonvoting industry representatives to serve on the committee. Nominees may be either self-nominated or nominated by an organization. Industry representatives must notify FDA of interest in participating in selection of nonvoting committee members by August 8, 2014; nomination materials are also due August 8, 2014.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
